Selection of surrogate marker genes in primary central nervous system lymphomas for radio-chemotherapy by DNA array analysis of gene expression profiles

  • Authors:
    • Ryuya Yamanaka
    • Shigeru Akutagawa
    • Fumiko Taguchi
    • Naoki Yajima
    • Naoto Tsuchiya
    • Takeo Uzuka
    • Ken Morii
    • Hideaki Takahashi
    • Ryuichi Tanaka
    • Nagahiro Saijo
    • Kazuto Nishio
  • View Affiliations

  • Published online on: October 1, 2003     https://doi.org/10.3892/ijo.23.4.913
  • Pages: 913-923
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Primary central nervous system lymphomas (PCNSLs) are extra nodal B-cell non-Hodgkin's lymphomas with primary manifestation in the brain, and their incidence has been increasing among both immunocompetent and immunocompromised populations. Samples of oligodendroglioma (n=5), glioblastoma (n=7), PCNSL (n=6), and normal brain (n=3) were studied (total of 21 samples) using cDNA array technology. The hierarchical clustering algorithm was used to obtain a phylogenetic tree, and it revealed a striking feature: PCNSL was clearly separated. The genes encoding laminin receptor 2, thioredoxin peroxidase, and elongation factor-1 were selected as specific genes in PCNSL by principal component analysis (PCA). When Mann-Whitney tests were performed to identify genes responsible for the differences between responders and non-responders to the treatment schedule for PCNSL, 76 known genes were found to show significantly different expression patterns between the two groups at the P<0.01 level. The two groups were clearly separated by the re-clustering method using the selected genes related to response to chemo-radiotherapy. This is the first report describing the gene expression profiles of PCNSL. In conclusion, accumulation of data with respect to the expression profiles of PCNSL specimens, clinicopathological data, susceptibility to treatment, and outcome will provide information for identifying optimal therapeutic modalities for individual patients and novel therapeutic targets.

Related Articles

Journal Cover

October 2003
Volume 23 Issue 4

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Yamanaka R, Akutagawa S, Taguchi F, Yajima N, Tsuchiya N, Uzuka T, Morii K, Takahashi H, Tanaka R, Saijo N, Saijo N, et al: Selection of surrogate marker genes in primary central nervous system lymphomas for radio-chemotherapy by DNA array analysis of gene expression profiles. Int J Oncol 23: 913-923, 2003
APA
Yamanaka, R., Akutagawa, S., Taguchi, F., Yajima, N., Tsuchiya, N., Uzuka, T. ... Nishio, K. (2003). Selection of surrogate marker genes in primary central nervous system lymphomas for radio-chemotherapy by DNA array analysis of gene expression profiles. International Journal of Oncology, 23, 913-923. https://doi.org/10.3892/ijo.23.4.913
MLA
Yamanaka, R., Akutagawa, S., Taguchi, F., Yajima, N., Tsuchiya, N., Uzuka, T., Morii, K., Takahashi, H., Tanaka, R., Saijo, N., Nishio, K."Selection of surrogate marker genes in primary central nervous system lymphomas for radio-chemotherapy by DNA array analysis of gene expression profiles". International Journal of Oncology 23.4 (2003): 913-923.
Chicago
Yamanaka, R., Akutagawa, S., Taguchi, F., Yajima, N., Tsuchiya, N., Uzuka, T., Morii, K., Takahashi, H., Tanaka, R., Saijo, N., Nishio, K."Selection of surrogate marker genes in primary central nervous system lymphomas for radio-chemotherapy by DNA array analysis of gene expression profiles". International Journal of Oncology 23, no. 4 (2003): 913-923. https://doi.org/10.3892/ijo.23.4.913